Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).

• Revenue in USD (TTM)83.57m
• Net income in USD-187.47m
• Incorporated2010
• Employees161.00

• Location
  Coherus Oncology IncC/O DENNIS M. LANFEAR201 REDWOOD SHORES PARKWAY, SUITE 200REDWOOD CITY 94065United StatesUSA
• Phone+1 (302) 658-7581
• Fax+1 (302) 655-5049
• Websitehttps://www.coherus.com/